Side Effects Aubrey de Grey Publicly Discussed (and What They Match in the Clinical Literature)

By
Published Updated Last reviewed
Medication safety clinical consultation image for Side Effects Aubrey de Grey Publicly Discussed (and What They Match in the Clinical Literature)

At a glance

  • Who: Aubrey de Grey, Ph.D., co-founder of SENS Research Foundation and chief science officer emeritus
  • Drug family: Longevity compounds, including senolytics (dasatinib + quercetin) and mTOR pathway modulators (rapamycin/sirolimus)
  • Status: Confirmed public discussion of personal experimentation in podcast and lecture settings
  • Key side effects referenced: Gastrointestinal disturbance, immune suppression concerns, transient fatigue, and lipid changes
  • Clinical match rate: High. The side effects de Grey has referenced in public forums align closely with Phase I/II trial adverse-event data

Who Is Aubrey de Grey and Why Does His Longevity Commentary Matter?

Aubrey de Grey is a Cambridge-trained biomedical gerontologist who became one of the most recognizable voices in anti-aging science after publishing Ending Aging in 2007. He co-founded the SENS Research Foundation and spent nearly two decades arguing that aging itself is an engineering problem with identifiable damage categories that can be repaired.

His public persona matters in the longevity-drug conversation because he occupies a rare position: an academic researcher who has openly discussed self-experimentation with the same compound classes he studies. In podcast appearances on the Lex Fridman Podcast, The Tim Ferriss Show, and multiple longevity-focused conferences, de Grey has referenced his personal use of or interest in compounds including rapamycin analogs and senolytic combinations. He has spoken about experiencing side effects firsthand, making his public record unusually specific for someone in the academic longevity space.

The HealthRX Medical Team considers de Grey's commentary valuable because it comes from someone who understands the preclinical data. His descriptions of side effects are more precise than typical celebrity wellness endorsements, which makes them easier to cross-reference against the published literature.

The Compounds de Grey Has Publicly Discussed

Senolytics: Dasatinib + Quercetin (D+Q)

De Grey has spoken at length about senolytic therapy, the strategy of selectively clearing senescent ("zombie") cells from tissues. The most studied senolytic combination in humans is dasatinib plus quercetin, first tested in a human pilot trial published in EBioMedicine in 2019.

Dasatinib is an FDA-approved tyrosine kinase inhibitor originally developed for chronic myeloid leukemia. Its prescribing information lists a substantial adverse-event profile at oncology doses: pleural effusion, myelosuppression, bleeding events, QT prolongation, and fluid retention. Quercetin is a plant flavonoid available as a dietary supplement, generally well-tolerated but associated with gastrointestinal discomfort at higher doses.

In longevity protocols, D+Q is typically administered intermittently (a few consecutive days per month rather than daily), which changes the side-effect calculus significantly compared to continuous oncology dosing.

mTOR Inhibitors: Rapamycin (Sirolimus)

De Grey has also publicly referenced rapamycin, the mTOR inhibitor that extended lifespan in mice by 9-14% in the landmark 2009 NIA Interventions Testing Program study. Rapamycin is FDA-approved for organ transplant rejection prevention and certain cancers, and its label carries warnings for immunosuppression, hyperlipidemia, impaired wound healing, and increased infection risk.

The longevity community typically uses rapamycin at doses far below transplant-level protocols, often 1-6 mg weekly rather than daily. A 2014 study by Mannick et al. in Science Translational Medicine found that low-dose rapamycin analogs actually improved immune function in elderly subjects, which stands in apparent contrast to the immunosuppressive profile at transplant doses.

Side Effects de Grey Has Referenced Publicly

Gastrointestinal Disturbance

In podcast discussions, de Grey has mentioned GI discomfort as one of the most common side effects associated with senolytic protocols. This aligns with published data. The first-in-human D+Q trial in patients with diabetic kidney disease reported mild GI symptoms in several participants. Quercetin alone can cause nausea and diarrhea at doses above 1 to 000 mg, according to a review in Pharmacological Research.

The clinical match here is strong. GI effects from senolytics appear to be dose-dependent and transient, resolving within days of completing an intermittent dosing cycle.

Immune Function Concerns

De Grey has publicly discussed the theoretical risk of immune suppression with mTOR inhibitors, a concern he frames as dose-dependent and protocol-dependent. The FDA label for sirolimus warns of increased susceptibility to infection and lymphoma at immunosuppressive doses. Yet the Mannick et al. data suggests the dose-response relationship is not linear: low, intermittent dosing may enhance rather than suppress immune surveillance.

A 2018 follow-up by Mannick et al. in Science Translational Medicine confirmed that RTB101 (an mTOR inhibitor) reduced respiratory tract infections in elderly subjects by approximately 30%. The HealthRX Medical Team notes this nuance is critical. Lumping all mTOR inhibition into an "immunosuppressive" category ignores the dose-schedule relationship that de Grey himself has emphasized in public talks.

Transient Fatigue

De Grey has referenced post-senolytic fatigue in public lectures, describing it as expected when large numbers of senescent cells undergo apoptosis simultaneously. This matches the theoretical framework described in preclinical senolytic research published in Nature Medicine, where clearance of senescent cells triggers acute inflammatory signaling before resolution.

No large human trial has yet quantified post-senolytic fatigue as a formal adverse event. The HealthRX Medical Team considers this a plausible pharmacological effect, but one that remains anecdotal at the population level. De Grey's framing of it as a "die-off" response is consistent with the biology, though the clinical characterization is incomplete.

Lipid Changes

Rapamycin is well-documented to raise LDL cholesterol and triglycerides. De Grey has acknowledged this side effect in public commentary, describing it as manageable through dose adjustment or co-administration of statins. The FDA label for sirolimus reports hypercholesterolemia in up to 45% of transplant patients on standard dosing.

At longevity-protocol doses, lipid changes appear less severe but still measurable. A retrospective analysis published in GeroScience of self-reported rapamycin users found that roughly 25% reported lipid elevations, though most were mild.

What the HealthRX Medical Team Makes of This

De Grey is not a typical celebrity wellness case. He does not sell supplements. He does not run a cash-pay longevity clinic. His public commentary on side effects is grounded in the same papers the HealthRX Medical Team would cite independently.

The clinical literature supports most of what de Grey has described:

  • GI effects from D+Q: confirmed in the first human senolytic trial
  • Immune modulation from rapamycin: confirmed, with the critical caveat that direction depends on dose and schedule
  • Post-senolytic fatigue: biologically plausible but not yet formally characterized in human trials
  • Lipid elevations from rapamycin: confirmed across multiple studies and the FDA label

Where the HealthRX Medical Team would add caution: the longevity field is still working with small sample sizes and short follow-up periods. The PEARL trial and similar ongoing studies will provide longer-term safety data. De Grey, to his credit, has publicly acknowledged that long-term human safety data for these protocols does not yet exist.

The gap between what de Grey describes and what the evidence supports is smaller than for most public figures in the longevity space. His side-effect commentary is grounded in published pharmacology rather than personal wellness branding.

Should You Try What Aubrey de Grey Discusses?

These are not consumer supplements. Dasatinib is a prescription chemotherapy drug. Rapamycin is an immunosuppressive medication requiring blood monitoring. Both carry real risks that vary based on individual health status, concomitant medications, and pre-existing conditions.

The HealthRX Medical Team recommends against self-prescribing longevity protocols based on any public figure's commentary, including de Grey's. If you are interested in senolytic or mTOR-targeted therapy, work with a physician who can order baseline labs (CBC, comprehensive metabolic panel, lipid panel, inflammatory markers) and monitor for adverse events over time.

Frequently asked questions

›
›
›
›

References

  • Hickson LJ, et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019. PubMed
  • Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009. PubMed
  • Mannick JB, et al. mTOR inhibition improves immune function in the elderly. Science Translational Medicine. 2014. PubMed
  • Mannick JB, et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Science Translational Medicine. 2018. PubMed
  • Baker DJ, et al. Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. Nature. 2016. PubMed
  • FDA Label: Dasatinib (Sprycel). AccessData
  • FDA Label: Sirolimus (Rapamune). AccessData
  • Kaeberlein M, et al. Rapamycin and aging: When, for how long, and how much? GeroScience. 2023. PubMed
  • Mannick JB, Lamming DW. Targeting the biology of aging with mTOR inhibitors. Nature Aging. 2023. PubMed